Return to search

Octant snags $80m Series B

Octant, Inc, a developer of programmable biology and chemistry to build precision medicines for complex diseases, has raised $80 million in Series B financing.

Octant, Inc, a developer of programmable biology and chemistry to build precision medicines for complex diseases, has raised $80 million in Series B financing. Catalio Capital Management led the round.

Source: Press Release